Show simple item record

dc.contributor.authorEconomou, CJP
dc.contributor.authorKielstein, JT
dc.contributor.authorCzock, D
dc.contributor.authorXie, J
dc.contributor.authorField, J
dc.contributor.authorRichards, B
dc.contributor.authorTallott, M
dc.contributor.authorVisser, A
dc.contributor.authorKoenig, C
dc.contributor.authorHafer, C
dc.contributor.authorSchmidt, JJ
dc.contributor.authorLipman, J
dc.contributor.authorRoberts, JA
dc.date.accessioned2019-12-23T04:37:59Z
dc.date.available2019-12-23T04:37:59Z
dc.date.issued2018
dc.identifier.issn0924-8579en_US
dc.identifier.doi10.1016/j.ijantimicag.2018.03.001en_US
dc.identifier.urihttp://hdl.handle.net/10072/389928
dc.description.abstractObjectives: The aim of this study was to describe the population pharmacokinetics of vancomycin during prolonged intermittent renal replacement therapy (PIRRT) in critically ill patients with acute kidney injury. Methods: Critically ill patients prescribed vancomycin across two sites had blood samples collected during one to three dosing intervals during which PIRRT was performed. Plasma samples were assayed with a validated immunoassay method. Population pharmacokinetic analysis and Monte Carlo simulations were performed using Pmetrics®. The target vancomycin exposures were the area under the concentration–time curve within a 24-h period (AUC0–24)/minimum inhibitory concentration (MIC) ratio of 400 for efficacy and AUC0–24 700 for toxicity. Results: Eleven critically ill patients (seven male) were enrolled and contributed 192 plasma samples. The patient's mean ± standard deviation (SD) age, weight and body mass index (BMI) were 57 ± 13 years, 98 ± 43 kg and 31 ± 9 kg/m2, respectively. A two-compartment linear model adequately described the data. The mean ± SD population pharmacokinetic parameter estimates were PIRRT clearance (CL) 3.47 ± 1.99 L/h, non-PIRRT CL 2.15 ± 2.07 L/h, volume of distribution of the central compartment (Vc) 41.85 ± 24.33 L, distribution rate constant from central to peripheral compartment 5.97 ± 7.93 per h and from peripheral to central compartment 5.29 ± 6.65 per h. Assuming a MIC of 1 mg/L, vancomycin doses of 25 mg/kg per day are suggested to be efficacious, whilst minimising toxic, exposures. Conclusions: This is the first population pharmacokinetic study of vancomycin in patients receiving PIRRT and we observed large pharmacokinetic variability. Empirically, weight-based doses that are appropriate for the duration of PIRRT, should be selected and supplemented with therapeutic drug monitoring.en_US
dc.description.peerreviewedYesen_US
dc.languageengen_US
dc.publisherElsevier BVen_US
dc.relation.ispartofpagefrom151en_US
dc.relation.ispartofpageto157en_US
dc.relation.ispartofissue2en_US
dc.relation.ispartofjournalInternational Journal of Antimicrobial Agentsen_US
dc.relation.ispartofvolume52en_US
dc.subject.fieldofresearchMedical Microbiologyen_US
dc.subject.fieldofresearchPharmacology and Pharmaceutical Sciencesen_US
dc.subject.fieldofresearchcode1108en_US
dc.subject.fieldofresearchcode1115en_US
dc.subject.keywordsAntibioticsen_US
dc.subject.keywordsDosingen_US
dc.subject.keywordsPharmacodynamicsen_US
dc.subject.keywordsPharmacokineticsen_US
dc.subject.keywordsProlonged intermittent renal replacement therapyen_US
dc.titlePopulation pharmacokinetics of vancomycin in critically ill patients receiving prolonged intermittent renal replacement therapyen_US
dc.typeJournal articleen_US
dc.type.descriptionC1 - Articlesen_US
dcterms.bibliographicCitationEconomou, CJP; Kielstein, JT; Czock, D; Xie, J; Field, J; Richards, B; Tallott, M; Visser, A; Koenig, C; Hafer, C; Schmidt, JJ; Lipman, J; Roberts, JA, Population pharmacokinetics of vancomycin in critically ill patients receiving prolonged intermittent renal replacement therapy, International Journal of Antimicrobial Agents, 2018, 52 (2), pp. 151-157en_US
dcterms.dateAccepted2018-03-02
dcterms.licensehttp://creativecommons.org/licenses/by-nc-nd/4.0/en_US
dc.date.updated2019-12-23T04:14:32Z
dc.description.versionPost-printen_US
gro.rights.copyright© 2018 Elsevier. Licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International Licence (http://creativecommons.org/licenses/by-nc-nd/4.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, providing that the work is properly cited.en_US
gro.hasfulltextFull Text
gro.griffith.authorRichards, Brent V.


Files in this item

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record